Erratum: Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections (J Antimicrob Chemother (2020) 75:9 (2384-2393) DOI: 10.1093/jac/dkaa183)

Adam G. Stewart; Patrick N.A. Harris; Andrew Henderson; Mark A. Schembri; David L. Paterson

doi:10.1093/JAC/DKAA424

Erratum: Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections (J Antimicrob Chemother (2020) 75:9 (2384-2393) DOI: 10.1093/jac/dkaa183)

Adam G. Stewart
, Patrick N.A. Harris
, Andrew Henderson
, Mark A. Schembri
, David L. Paterson

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the original published version of this article there was an error in the section entitled 'Novel b-lactamase inhibitors in combination with ceftibuten or cefpodoxime'. The sentence 'VNRX7145 is another b-lactamase inhibitor that undergoes biotransformation to the active VNRX5236 with potent activity against Class A, B and C enzymes.' should have read 'VNRX7145 is another b-lactamase inhibitor that undergoes biotransformation to the active VNRX5236 with potent activity against Class A, C and D enzymes, but not Class B.' This error has now been corrected in the online version of the article. The authors apologize for this error. This has nowbeen corrected online.

Original language	English (US)
Pages (from-to)	281
Number of pages	1
Journal	Journal of Antimicrobial Chemotherapy
Volume	76
Issue number	1
DOIs	https://doi.org/10.1093/JAC/DKAA424
State	Published - 2021
Externally published	Yes

ASJC Scopus subject areas

Pharmacology
Microbiology (medical)
Infectious Diseases
Pharmacology (medical)

Access to Document

10.1093/JAC/DKAA424

Fingerprint

Dive into the research topics of 'Erratum: Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections (J Antimicrob Chemother (2020) 75:9 (2384-2393) DOI: 10.1093/jac/dkaa183)'. Together they form a unique fingerprint.

Cite this

Stewart, A. G., Harris, P. N. A., Henderson, A., Schembri, M. A., & Paterson, D. L. (2021). Erratum: Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections (J Antimicrob Chemother (2020) 75:9 (2384-2393) DOI: 10.1093/jac/dkaa183). Journal of Antimicrobial Chemotherapy, 76(1), 281. https://doi.org/10.1093/JAC/DKAA424

Erratum: Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections (J Antimicrob Chemother (2020) 75:9 (2384-2393) DOI: 10.1093/jac/dkaa183). / Stewart, Adam G.; Harris, Patrick N.A.; Henderson, Andrew et al.
In: Journal of Antimicrobial Chemotherapy, Vol. 76, No. 1, 2021, p. 281.

Research output: Contribution to journal › Comment/debate › peer-review

Stewart, AG, Harris, PNA, Henderson, A, Schembri, MA & Paterson, DL 2021, 'Erratum: Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections (J Antimicrob Chemother (2020) 75:9 (2384-2393) DOI: 10.1093/jac/dkaa183)', Journal of Antimicrobial Chemotherapy, vol. 76, no. 1, pp. 281. https://doi.org/10.1093/JAC/DKAA424

@article{24fc931c26984f1cb29ae8169614ec50,

title = "Erratum: Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections (J Antimicrob Chemother (2020) 75:9 (2384-2393) DOI: 10.1093/jac/dkaa183)",

abstract = "In the original published version of this article there was an error in the section entitled 'Novel b-lactamase inhibitors in combination with ceftibuten or cefpodoxime'. The sentence 'VNRX7145 is another b-lactamase inhibitor that undergoes biotransformation to the active VNRX5236 with potent activity against Class A, B and C enzymes.' should have read 'VNRX7145 is another b-lactamase inhibitor that undergoes biotransformation to the active VNRX5236 with potent activity against Class A, C and D enzymes, but not Class B.' This error has now been corrected in the online version of the article. The authors apologize for this error. This has nowbeen corrected online.",

author = "Stewart, \{Adam G.\} and Harris, \{Patrick N.A.\} and Andrew Henderson and Schembri, \{Mark A.\} and Paterson, \{David L.\}",

year = "2021",

doi = "10.1093/JAC/DKAA424",

language = "English (US)",

volume = "76",

pages = "281",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Erratum

T2 - Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections (J Antimicrob Chemother (2020) 75:9 (2384-2393) DOI: 10.1093/jac/dkaa183)

AU - Stewart, Adam G.

AU - Harris, Patrick N.A.

AU - Henderson, Andrew

AU - Schembri, Mark A.

AU - Paterson, David L.

PY - 2021

Y1 - 2021

N2 - In the original published version of this article there was an error in the section entitled 'Novel b-lactamase inhibitors in combination with ceftibuten or cefpodoxime'. The sentence 'VNRX7145 is another b-lactamase inhibitor that undergoes biotransformation to the active VNRX5236 with potent activity against Class A, B and C enzymes.' should have read 'VNRX7145 is another b-lactamase inhibitor that undergoes biotransformation to the active VNRX5236 with potent activity against Class A, C and D enzymes, but not Class B.' This error has now been corrected in the online version of the article. The authors apologize for this error. This has nowbeen corrected online.

AB - In the original published version of this article there was an error in the section entitled 'Novel b-lactamase inhibitors in combination with ceftibuten or cefpodoxime'. The sentence 'VNRX7145 is another b-lactamase inhibitor that undergoes biotransformation to the active VNRX5236 with potent activity against Class A, B and C enzymes.' should have read 'VNRX7145 is another b-lactamase inhibitor that undergoes biotransformation to the active VNRX5236 with potent activity against Class A, C and D enzymes, but not Class B.' This error has now been corrected in the online version of the article. The authors apologize for this error. This has nowbeen corrected online.

UR - https://www.scopus.com/pages/publications/85098451755

UR - https://www.scopus.com/pages/publications/85098451755#tab=citedBy

U2 - 10.1093/JAC/DKAA424

DO - 10.1093/JAC/DKAA424

M3 - Comment/debate

C2 - 33111952

AN - SCOPUS:85098451755

SN - 0305-7453

VL - 76

SP - 281

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 1

ER -

Erratum: Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections (J Antimicrob Chemother (2020) 75:9 (2384-2393) DOI: 10.1093/jac/dkaa183)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this